Business
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger an
About this update from Alumis Inc.
[{"type":"image","alt":"ACELYRIN, INC.","displaySize":"","headline":null,"caption":"ACELYRIN, INC.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":41,"url":"https://media.zenfs.com/en/globenewswire.com/ea5891d840adcef28072e5fd0bfe88c1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oMbYCXmMGd9UojWULe6c8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ea5891d840adcef28072e5fd0bfe88c1","width":300,"height":41}},"lazy":false},{"type":"text","content":"ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis","length":242,"tagName":"p"},{"type":"text","content":"Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ","length":176,"tagName":"p"},{"type":"text","content":"ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process ","length":109,"tagName":"p"},{"type":"text","content":"Special Meeting of Stockholders for both companies to be held May 13, 2025","length":74,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced an amendment to the existing terms of their previously announced merger agreement.","length":577,"tagName":"p"},{"type":"text","content":"Under the terms of the amended agreement, ACELYRIN stockholders will now receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, representing a meaningful increase in the ownership percentage of the combined company over the original definitive merger agreement. With the amended exchange ratio, Alumis stockholders will own approximately 52% of the combine...